Dexrazoxane
Dexrazoxane is an iron chelator that exhibits cardioprotective, antioxidative, pro-angiogenic, and anti-parasitic activities. Dexrazoxane decreases superoxide formation and prevents anthracycline-induced cardiotoxicity. In animal models of myocardial infarction, dexrazoxane decreases infarct size, increases capillary density, and improves cardiac function. Additionally, this compound displays antimalarial benefit, inhibiting growth of Plasmodium.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1885980
| Cas No. |
24584-09-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C11H6N4O4 |
| Formula Wt. |
268.27 |
| IUPAC Name |
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione |
| Appearance |
White to off white powder |
Doroshow JH. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics. Curr Pharm Biotechnol. 2012 Aug;13(10):1949-56. PMID: 22352729.
Zhou L, Sung RY, Li K, et al. Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis. Int J Cardiol. 2011 Oct 20;152(2):196-201. PMID: 20692056.
Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1311-7. PMID: 19018683.
Loyevsky M, Sacci JB Jr, Boehme P, et al. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PMID: 9990337.
